Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Feb;36(2):498–501. doi: 10.1128/aac.36.2.498

In vitro and in vivo activities of SCH 42427, the active enantiomer of the antifungal agent SCH 39304.

D Loebenberg 1, A Cacciapuoti 1, R Parmegiani 1, E L Moss Jr 1, F Menzel Jr 1, B Antonacci 1, C Norris 1, T Yarosh-Tomaine 1, R S Hare 1, G H Miller 1
PMCID: PMC188469  PMID: 1605621

Abstract

SCH 39304, a new triazole antifungal agent, is a 50:50 racemic mixture of two enantiomers, SCH 42427 and SCH 42426. The activities of these three compounds were compared in a series of in vitro and in vivo experiments. SCH 42427 was twofold more active in vitro against a variety of yeasts and dermatophytes than SCH 39304, while SCH 42426 was inactive (MICs greater than 64 micrograms/ml). In a systemic Candida albicans infection in mice, SCH 42427 administered orally (p.o.) (50% protective dose [PD50], 0.17 mg/kg of body weight; 50% effective dose, [ED50], 0.47 mg/kg) had greater efficacy than SCH 39304 (PD50, 0.21 mg/kg; ED50, 0.62 mg/kg) and SCH 42426 (greater than 100 mg/kg for PD50 and ED50). In a pulmonary Aspergillus flavus infection in mice, SCH 42427 p.o. (PD50, 13 mg/kg) was also more effective than SCH 39304 (18 mg/kg) and SCH 42426 (greater than 250 mg/kg). In a C. albicans vaginal infection in hamsters, SCH 42427 p.o. (ED50, 3.5 mg/kg) was more active than SCH 39304 (8.5 mg/kg) and SCH 42426 (320 mg/kg). Following topical administration, against a Trichophyton mentagrophytes infection in guinea pigs, SCH 42427 was about 2-fold more active than SCH 39304 and about 100-fold more active than SCH 42426. These and other results indicated that SCH 42427 is the active enantiomer, responsible for all the antifungal activity observed with SCH 39304.

Full text

PDF
498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allendoerfer R., Yates R. R., Marquis A. J., Loebenberg D., Rinaldi M. G., Graybill J. R. Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis. Antimicrob Agents Chemother. 1992 Jan;36(1):217–219. doi: 10.1128/aac.36.1.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cacciapuoti A., Loebenberg D., Parmegiani R., Antonacci B., Norris C., Moss E. L., Jr, Menzel F., Jr, Yarosh-Tomaine T., Hare R. S., Miller G. H. Comparison of SCH 39304, fluconazole, and ketoconazole for treatment of systemic infections in mice. Antimicrob Agents Chemother. 1992 Jan;36(1):64–67. doi: 10.1128/aac.36.1.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clemons K. V., Hanson L. H., Perlman A. M., Stevens D. A. Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother. 1990 May;34(5):928–930. doi: 10.1128/aac.34.5.928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cook R. A., McIntyre K. A., Galgiani J. N. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother. 1990 Aug;34(8):1542–1545. doi: 10.1128/aac.34.8.1542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Defaveri J., Sun S. H., Graybill J. R. Treatment of murine coccidioidal meningitis with SCH39304. Antimicrob Agents Chemother. 1990 Apr;34(4):663–664. doi: 10.1128/aac.34.4.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kobayashi G. S., Travis S. J., Rinaldi M. G., Medoff G. In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum. Antimicrob Agents Chemother. 1990 Apr;34(4):524–528. doi: 10.1128/aac.34.4.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. McIntyre K. A., Galgiani J. N. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother. 1989 Jul;33(7):1095–1100. doi: 10.1128/aac.33.7.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Meunier F., Lambert C., Van der Auwera P. In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole. J Antimicrob Chemother. 1990 Feb;25(2):227–236. doi: 10.1093/jac/25.2.227. [DOI] [PubMed] [Google Scholar]
  9. PIGGOTT W. R., EMMONS C. W. Device for inhalation exposure of animals to spores. Proc Soc Exp Biol Med. 1960 Apr;103:805–806. doi: 10.3181/00379727-103-25677. [DOI] [PubMed] [Google Scholar]
  10. Perfect J. R., Wright K. A., Hobbs M. M., Durack D. T. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304. Antimicrob Agents Chemother. 1989 Oct;33(10):1735–1740. doi: 10.1128/aac.33.10.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Restrepo B. I., Ahrens J., Graybill J. R. Efficacy of SCH39304 in murine cryptococcosis. Antimicrob Agents Chemother. 1989 Aug;33(8):1242–1246. doi: 10.1128/aac.33.8.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sugar A. M., Picard M., Noble L. Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent. Antimicrob Agents Chemother. 1990 May;34(5):896–898. doi: 10.1128/aac.34.5.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tanio T., Ichise K., Nakajima T., Okuda T. In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrob Agents Chemother. 1990 Jun;34(6):980–984. doi: 10.1128/aac.34.6.980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Walsh T. J., Lee J. W., Lecciones J., Kelly P., Peter J., Thomas V., Bacher J., Pizzo P. A. SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob Agents Chemother. 1990 Aug;34(8):1560–1564. doi: 10.1128/aac.34.8.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES